Navigation Links
Pharmos Corporation Completes Initial Closing of Private Placement
Date:1/3/2008

ISELIN, N.J., Jan. 3 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS) announced today that it has completed an initial closing of a private placement of its 10% Convertible Debentures due November 2012. At the initial closing the Company issued $4,000,000 principal amount of the Debentures, at par, and received gross proceeds in the same amount.

The purchasers consisted of certain existing investors in the Company, namely Venrock Associates, New Enterprise Associates, Lloyd I. Miller, III and Robert Johnston.

The Debentures mature the earlier of November 1, 2012 or the sale of the Company. The Debentures, together with all accrued and unpaid interest thereon, may be repaid, without premium or penalty, commencing on November 1, 2011.

Starting on November 1, 2009 (or earlier sale of the Company), any outstanding Debenture may be converted at the option of the holder. The conversion price is fixed equal to $0.70 per share.

The Debentures bear interest at the rate of 10% per annum, payable semi-annually either in cash or common stock of the Company at the option of the Company.

Under the terms of the offering, the Company may raise gross proceeds up to an aggregate of $8,000,000 from the sale of Debentures in the placement (including the Debentures issued at the initial closing). A second closing is targeted for no later than 45 days from the date of the initial closing.

The proceeds will be used for working capital, in particular for the ongoing Phase 2b trial for dextofisopam.

The securities issued and issuable in the offering have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or applicable
'/>"/>

SOURCE Pharmos Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pharmos Corporation Announces Board and Management Changes
2. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
3. Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference
4. Pharmos Corporation Reports 2007 Third Quarter Results
5. Pharmos Issues Letter to Shareholders
6. Environmental Tectonics Corporation Announces Sale of Monoplace Hyperbaric Chambers
7. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
8. LifeCell Corporation Schedules 2008 Financial Guidance Release and Conference Call; January 7, 2008 at 10:00 A.M. Eastern
9. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
10. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
11. FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of ... the three months and full year ended December ... Results:Revenue for the quarter ended December 31, 2014 ... fourth quarter of 2013 and $1.5 million for ...
(Date:3/26/2015)... The Market Element LLC, a leading inbound marketing ... Gig LLC to provide website design, development, and creative ... alliance with Designing Gig represents a pivotal moment for ... end-to-end, digital solution for our clients, which now includes ... president of The Market Element. “For small and mid-sized ...
(Date:3/26/2015)... 26, 2015 Neogen Corporation (NASDAQ: NEOG ... third quarter of fiscal 2015, which ended Feb. 28, ... year,s $6,575,000. Earnings per share in the current quarter ... year-to-date net income increased 17% over prior year to ... $0.56 per share, for the same period a year ...
(Date:3/26/2015)... March 26, 2015 "In America," the popular ... United States that is hosted by legendary film actor James ... of botany in an upcoming segment. , Botany is ... reality it is actually quite a bit more complicated than ... different types of living organisms, from the smallest bacteria known ...
Breaking Biology Technology:Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8
... Drives Physician Prescribing of Copaxone over an Interferon-Beta Therapy, According ... ... Resources, WALTHAM, Mass., March 11 Decision ... pharmaceutical and,healthcare issues, finds that Teva Pharmaceutical,s Copaxone has the,greatest patient ...
... Biosystems,( http://www.altogen.com ) announced launch of new ... Altogen Custom Services focus on,providing specialized biotechnology ... generation of stably-expressing cell,lines, assay development, screening ... draw upon their unique experience with over,hundred ...
... -Advances Reported in All Three Clinical Programs, Including Launch of ... Bavituximab Phase ... Inc. (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company developing ... (HCV) infection, today announced financial results for,the third quarter of ...
Cached Biology Technology:Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 2Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 3Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services 2Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 2Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 4Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 5Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 6Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 7Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 8Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 9Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 10
(Date:3/5/2015)... , March 5, 2015 In Brazil ... of companies already using these solutions and 42 percent planning ... the latter, approximately 25 percent of the companies will be ... While the majority of companies in the region are currently ... the hybrid model will command significant attention in the coming ...
(Date:3/3/2015)... , March 3, 2015 ... provider of advanced cryogenic logistics solutions for ... immunotherapies, stem cells, cell lines, clinical research ... medicine, today announced the expansion of its ... Centers, ("Fred Hutch") Clinical Research Division ...
(Date:3/2/2015)... March 2, 2015  Businesses have a new ... company Tharon Rankins Enterprises has announced the launch ... ultra-safe way for businesses to protect their customers, ... Beconux is a biometric transaction ... Functioning similarly to an ATM machine, the new ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Personal Data Protection Company Launches New Product 2
... GAINESVILLE, Fla. The wild pea pod is big and ... its parent plant. And yet, like a grounded teenager ... if it has a reasonable chance of escape. ... landscape devoted to wildlife corridors greenways that link woods ...
... Scientists from Scripps Institution of Oceanography at UC ... have captured unprecedented details of vibrant sea life ... documentations of new species and marine animals previously ... surveys at unexplored depths, have revealed disturbing declines ...
... the United States continues to develop alternative energy methods ... as one of the most commercially viable technologies. Corn ... loss of soil organic carbon (SOC) associated with the ... is of agricultural and environmental concern. ...
Cached Biology News:Rooted plants move mysteriously down greenways, scientists say 2Rooted plants move mysteriously down greenways, scientists say 3Expeditions reveal gulf of California's deep sea secrets, as well as human imprints 2Expeditions reveal gulf of California's deep sea secrets, as well as human imprints 3Expeditions reveal gulf of California's deep sea secrets, as well as human imprints 4Managing carbon loss 2
... The Corning CellBIND surface is produced by ... more hydrophilic surface giving more consistent, even ... CellBIND enhances cell attachment and growth uunder ... medium. • CellBIND may provide a more ...
... The Infinite 200 series of microplate ... or absorbance detection in an affordable, easy-to-use ... science applications. The unique modular design and ... researchers with a choice of a monochromator ...
Mouse polyclonal antibody raised against a partial recombinant RDH5. NCBI Entrez Gene ID = 5959...
... ,High Quality, Functionally-Validated, Ion Channel Cell Lines ... having a critical role in nerve and ... function in pain, CNS and the heart. ... investigated in therapeutic areas, such as neuropathic ...
Biology Products: